Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Joby Aviation has shed a fifth of its value in a single month while the broader market climbed, and the reasons point to something bigger than one company's bad stretch.

SpaceX's plan to bypass terrestrial cell towers with satellite-linked femtocells faces insurmountable technical, economic, and regulatory barriers, especially in urban areas. Some parts of the plan are downright comical and appear to have no grounding in reality. We assign a Strong Sell to SpaceX (SPCX) due to its speculative valuation and unproven business model, while legacy telecoms offer compelling risk-reward.

The sector set to lead another quarter of corporate profit growth is

LOS ANGELES, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 30, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fluence Energy, Inc. (“Fluence” or the “Company”) (NASDAQ: FLNC) securities between November 24, 2025 and September 16, 2026 inclusive (the “Class Period”).

Intel and AMD have each tripled their value in a matter of months, leaving shareholders staring down a decision that cuts both ways. The case for staying in is compelling, and so is the case for walking away.

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Bluerock Homes Trust, Inc. (NYSE American: BHM) (the "Company") today announced that its Board of Directors has authorized and the Company has declared monthly cash dividends on the Company's Series A Redeemable Preferred Stock (the "Series A Preferred Stock") for the fourth quarter of 2026, equal to a quarterly rate of $0.375 per share (the "Series A Preferred Dividends").  In addition, the Board of Directors has authorized and the Company has declared monthly cash dividends on its Series B Redeemable Preferred Stock (the "Series B Preferred Stock") for the fourth quarter of 2026, equal to a quarterly rate of $0.46875 per share (the "Series B Preferred Dividends").

ASML Holding N.V. will raise prices by 10% on any and all replacement plus maintenance parts for two of its largest customers, Samsung and SK hynix, effective January. While such an across-the-board increase is unusual for ASML, it'll likely incentivize faster lithography tool upgrades for the mid-term and generate higher Installed Base revenue in the near-term. We expect two things from ASML's print this Wednesday: a better-than-expected Q4 guide and more detail on ASML's pricing plans.

Astrazeneca NYSE: AZN presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research annual meeting in Boston. The company said the therapy showed improvements in several measures of function, pain and fatigue in adolescents and adults, although the HICKORY trial did not meet its primary endpoint.